News

Findings from the S1619 trial signal that a neoadjuvant triplet is safe and effective for the treatment of resectable mesothelioma.

Enrollment has been completed in the VERSATILE-002 trial, a phase 2 study of PDS0101 for the treatment of advanced human papillomavirus-associated head and neck cancer that has returned or spread.

Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Roughly 50% of patients with clear cell renal cell carcinoma responded to the combination of nivolumab plus ipilimumab in a Japanese study, and varied responses occurred in those with nonclear cell histology.

Compared to those who are overweight or of a normal weight, patients who are obese are more likely to have better disease-specific and overall survival in metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, John Diaz, MD, discussed the ovarian cancer treatment paradigm and the promise of STRO-002 for an important ovarian cancer subgroup.

The FDA has granted a breakthrough device designation to the NovoTTF-200T System, a tumor treating fields delivery system, for the treatment of unresectable or metastatic liver cancer.

Results from a phase 1/2 study showed a high rate of objective response with mobocertinib in a subset of patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Data from an exploratory analysis of the phase 3 IMpower010 trial show the disease-free survival benefit of adjuvant atezolizumab in the treatment of early-stage non–small cell lung cancer.

The first patient has been dosed in the phase 1b/2 trial of ERAS-007, an extracellular signal-regulated kinase inhibitor, for the treatment of advanced non-small cell lung cancer.

Onvansertib has demonstrated positive efficacy and safety in patients with KRAS-mutant metastatic colorectal cancer.

The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.

Alicia K. Morgans, MD, PhD, discusses the cardiovascular risks associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer.

Sotorasib leads to intracranial responses in patients with KRAS G12C-mutated non–small cell lung cancer, according to an update from CodeBreaK 100.

Zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, was safe and effective in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma carrying chromosome 17p13.1 deletion.

In an interview, Amaia Lujambio, MD discussed the diversity of genomic alterations in hepatocellular and advanced in molecular testing that could shape future understanding of the disease.

In an interview with Targeted Oncology, Michael Kolodziej, MD, the senior advisor for ADVI Health as well as an American College of Physicians Fellow, discussed the impact the COVID-19 pandemic has had on oncology practice. 

The addition of ramucirumab to gemcitabine in the second-line setting led a survival advantage for patients malignant pleura mesothelioma.

Bishoy M. Faltas, MD, discussed the use of genomic testing in urothelial canncer in greater detail, in an interview with Targeted Oncology.

The phase 2 NOVA-II study has completed its part 1 analysis of OQL011 for the treatment of cancer therapy-induced skin toxicities.

Elisa Agostinetto, MD, of the Istituto Clinico Humanitas in Rozzano, Milan, Italy, discussed the rational of investigating the accuracy of PREDICT+ in HER2-positive breast cancer.

A study has shown that high interferon signaling and expression of MHC-II related genes can predict response to therapy is patients with advanced heptocellular carcinoma being treated for the first time.

Atezolizumab given in combination with bevacizumab led to an improvement in overall survival compared with sorafenib in patients with albumin-bilirubin grade 1 hepatocellular carcinoma.

Cancer research sites across the United States are evaluating the use of TTI-622 plus azacitidine in patients with T53-mutated acute myeloid leukemia.

Patients with inoperable intrahepatic cholangiocarcinoma have demonstrated tendency to live longer when elective internal radiation therapy with Y90 is added to chemotherapy.

Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.

In an interview with Targeted Oncology™, Rajneesh Nath, MD, discussed the need for novel treatment for elderly patients with relapsed/refractory AML and how the SIERRA trial is designed to help.

Retrospective data show a low prevalence of esophagitis among immune checkpoint inhibitor-related adverse event in patient with cancer.

In an interview with Targeted Oncology, Rodney P. Rocconi, MD, FACOG, discussed the analysis of the homologous recombination proficient patients with advanced-stage ovarian cancer treated in the phase 2 VITAL study as well as a biomarker analysis.

Clinicians affiliated with the National Community Oncology Dispensing Association, Inc have launched the Intravenous Cancer Treatment Education website, as educational resource for patients.